Vir Biotechnology, Inc. reports developments as a clinical-stage biopharmaceutical company developing medicines for serious infectious diseases and cancer. Recurring updates cover its chronic hepatitis delta program, including the investigational combination of tobevibart and elebsiran, and its oncology portfolio of PRO-XTEN® dual-masked T-cell engagers across solid tumor targets.
Company news also includes clinical data presentations, trial progress, financial results, equity financing activity, and strategic collaborations. Its VIR-5500 program is a PSMA-targeted PRO-XTEN® dual-masked T-cell engager for metastatic prostate cancer, and the company also describes preclinical work across infectious diseases and oncologic malignancies.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Vir Biotechnology announced that Dr. Phil Pang, its Chief Medical Officer, will participate in a fireside chat during the 22nd Annual Needham Virtual Healthcare Conference on April 18, 2023, at 12:00 p.m. PT / 3:00 p.m. ET.
Investors can access a live webcast of the presentation in the Investors section of the Vir website, which will also be archived for 30 days.
Vir Biotechnology is dedicated to treating and preventing serious infectious diseases by leveraging innovative technologies and immunologic insights. Their development pipeline includes candidates targeting COVID-19, hepatitis B and D, influenza A, and HIV.
Vir Biotechnology announced that Phil Pang, M.D., Ph.D., Executive Vice President and Chief Medical Officer, will present at the Barclays Global Healthcare Conference on March 15, 2023, at 7:15 a.m. PT / 10:15 a.m. ET. A live webcast of this presentation will be available on their website under the Events & Presentations section and archived for 30 days.
Vir Biotechnology is a commercial-stage immunology company focused on treating and preventing serious infectious diseases through innovative technology platforms. Their pipeline includes candidates for COVID-19, hepatitis B and D, influenza A, and HIV.
Vir Biotechnology has announced that Bolyn Hubby, Ph.D., the Executive Vice President and Chief Corporate Affairs Officer, will participate in a panel about infectious diseases at the Cowen 43rd Annual Health Care Conference. This event is scheduled for March 7, 2023, at 6:10 a.m. PT / 9:10 a.m. ET. A live webcast of the panel will be available on the Vir website under the Events & Presentations section and will remain accessible for 30 days.
Vir Biotechnology focuses on innovative solutions to treat serious infectious diseases through advanced immunological technologies. Its development pipeline includes candidates for COVID-19, hepatitis B and D, influenza A, and HIV.
Vir Biotechnology reported a significant year in 2022, recognizing $1.5 billion in collaboration revenue from sotrovimab. The company has a robust financial position with approximately $2.4 billion in cash and investments, allowing it to fund ongoing clinical trials in hepatitis B, hepatitis D, and influenza. Notable leadership transitions were announced, including the retirement of CEO George Scangos, effective April 3, 2023, and the appointment of Marianne De Backer as his successor. The company anticipates critical Phase 2 trial data and continues to progress in addressing COVID-19 and other infectious diseases.